Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. The prevalence of fibromyalgia is estimated to be 2 to 6 percent of the
The two scientific posters listed below will be presented live on
- Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation (TENS) May Improve Self-Reported Balance Impairment in Subjects with Fibromyalgia: An Exploratory Post-Hoc Analysis
Balance impairment and falls are common in individuals with fibromyalgia. Data from a recently completed double-blind, randomized, sham-controlled trial of Quell in 119 subjects with fibromyalgia was analyzed. Self-reported balance impairment was assessed on an 11-point numerical rating scale. The median balance at baseline was 5 (IQR 2-7). Balance impairment decreased following 3-months of active (-1.32±0.30, p<0.001) but not sham (-0.35±0.34, p=0.300) treatment. The group difference was significant (-0.97±0.46, p=0.039). Quell may improve self-reported balance impairment in patients with fibromyalgia.
- Fibromyalgia Patients with Self-Reported Weather Insensitivity Exhibit an Enhanced Treatment Response to Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation (TENS)
Most individuals with fibromyalgia report that weather changes exacerbate their symptoms. However, little is known about the minority that is insensitive to the effects of weather. An analysis of real-world data from 766 individuals with fibromyalgia was conducted. Participants without weather sensitivity reported greater reductions in pain-intensity, pain-interference with sleep and pain-interference with activity compared to those with weather sensitivity. If the treatment benefits of weather insensitivity can be determined, it may be possible to optimize outcomes in the overall population of fibromyalgia patients.
"We are pleased to contribute to the unmet need for safe and effective treatments for people with fibromyalgia.
Quell Fibromyalgia Indications
Quell Fibromyalgia is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The device may be used during sleep.
The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109. The product labeling should be reviewed for a complete list of contraindications, precautions and warnings.
For more information visit www.QuellFibromyalgia.com.
About Quell Technology
Quell is an advanced, non-invasive, neuromodulation technology that is covered by 24 U.S. utility patents. It is the only wearable neuromodulator that is enabled by a proprietary microchip to provide precise, high-power nerve stimulation in a form factor the size of a credit card. Quell utilizes position and motion sensing to automatically adjust stimulation for an optimal user experience both day and night. The device supports Bluetooth® low energy (BLE) to communicate with mobile apps for multiple smartphone platforms.
SVP and Chief Financial Officer
Source: NeuroMetrix, Inc.